Presentation (CTI)

OBJECTIVES: Patient-experienced data (PED) are increasingly seen as valuable evidence in health technology assessments (HTAs). They are widely used in the United States and Europe and are growing in the Asia-Pacific (APAC). This study reviews PED use in HTA decisions across four countries: Australia (AU), Taiwan (TW), South Korea (KR), and Singapore (SG).
METHODS: A targeted review of publicly available HTA reports, published between 2020 and 2024 in four APAC markets, was conducted using keywords related to PED, such as quality of life and patient-reported outcomes, to identify relevant reports. Treatments, drug indications, and evidence generation methods for PED were extracted and analyzed.
RESULTS: Out of 650 reports screened, 232 reports with positive decisions were analyzed. PED was utilized across various therapeutic areas, notably in pediatrics, central nervous system, cancer, and rare diseases. Approximately 40% of PED were reported as primary or secondary endpoints. However, HTA decision-makers' interpretation and utilization of PED remain unclear, indicating a need for greater transparency. PEDs were commonly included in cancer assessments but were generally used as supplementary evidence. For non-life-threatening but chronic conditions, PEDs more often served as primary endpoints in 62% of cases. Most evidence was generated from randomized controlled trials, with limited contributions from observational studies. PED generation methods varied by market. In AU, PED incorporated a consultation of consumer opinion, which included feedback from patients and disease associations. In TW, local PED was often generated through patient opinion, facilitated by online sharing platforms.
CONCLUSIONS: While the use of PED is evolving, it demonstrates potential in contributing to HTA evaluations, particularly for complex and chronic conditions. To achieve more comprehensive and patient-centered HTA outcomes, there is a need for increased transparency and standardized methods for integrating PED.